丹红注射液联合依达拉奉治疗急性进展性脑梗死临床研究

Danhong Injection with Edaravone for Treatment of Acute Evolving Cerebral Infarction

目的观察丹红注射液联合依达拉奉治疗急性进展性脑梗死的疗效及安全性。方法选择发病72h内的急性进展性脑梗死患者160例,随机分为治疗组(81例)及对照组(79例),治疗组予丹红注射液联合依达拉奉治疗;对照组予丹红注射液治疗。观察2周后神经功能缺损评分和日常生活能力评分的变化,随时记录用药的不良反应。结果治疗组神经功能缺损评分较对照组下降明显,日常生活能力评分较对照组明显提高,两组比较差异有统计学意义(P<0.01);治疗组显效率及总有效率为61.7%和84.0%,对照组显效率及总有效率为44.3%和67.1%,两组比较有统计学意义(P<0.05)。各项安全性指标检测在正常范围。结论丹红注射液联合依达拉奉治疗急性进展性脑梗死的疗效显著,且安全无毒副反应。

Objective To study the effect of Danhong injection with edaravone for treatment of acute evolving cerebral infarction （ECI）. Methods One hundred and sixty patients （pts） with acute evolving cerebral infarction were enrolled and divided randomly into Danhong group treated with Danhong injection （n=79）, Danhong with edaravone group （n= 81） treated with Danhong injection and edaravone. Before and after treatment for two weeks, the clinical nervous function defect degree and activities of daily living （ADL） were evaluated using the nervous defect standard （NDS） and barthel index respectively. Curative effect and side effects were observed. Results The clinical nervous function defect degree was significant difference in two groups before and after treatment and that in Danhong with edaravone group was less than that in other group （P〈0.01）. There was an evidently difference of ADL before and after treatment in two groups （P〈0.05）. The total efficiency and significant efficiency in Danhong with edaravone group was 61.7% and 84%. That were obviously higher than that（44.3% and 67.1%）in other group （P〈0.01）, There were no obvious side effects. Conclusion Danhong injection with edaravone could improve nerve function and they were safe and effective for treatment of acute evolving cerebral infarction.